



Integra LifeSciences to Host Analyst Forum On November 17, 2008

PLAINSBORO, N.J., Oct 7, 2008 (GlobeNewswire via COMTEX News Network) -- Integra LifeSciences Holdings Corporation (Nasdaq:IART) announced today that it will host the annual Analyst Forum on Monday, November 17, 2008 from 2:00 to 5:00 PM Eastern Time at the New York Marriott East Side Hotel in New York City. The meeting hosted by Stuart Essig, Integra LifeSciences' President and Chief Executive Officer, will feature an overview of our business, a discussion of our products and pipeline, and our strategy for future growth.

The Analyst Forum is open to all analysts and investors. For in person attendance, please RSVP by November 11, 2008 via email to Kwang.wen@integra-ls.com. Access to the live presentation will be available by dialing 913-312-1300, pass code 2597748 or through a webcast via a link provided on the Investor Relations homepage of Integra's website at www.Integra-LS.com. Listeners participating by telephone or webcast will not be able to ask questions during the question and answer session.

A replay of the Analyst Forum will be accessible three hours after the conclusion of the live event. Access to the replay will be available through December 1, 2008 by dialing 719-457-0820 (access code 2597748) or through the webcast.

Integra LifeSciences Holdings Corporation, a world leader in regenerative medicine, is dedicated to improving the quality of life for patients through the development, manufacturing, and marketing of cost-effective surgical implants and medical instruments. Our products, used primarily in neurosurgery, extremity reconstruction, orthopedics and general surgery, are used to treat millions of patients every year. Integra's headquarters are in Plainsboro, New Jersey, and we have research and manufacturing facilities throughout the world. Please visit our website at (<http://www.Integra-LS.com>).

Statements made at the Analyst Forum may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties that could cause actual results to differ from predicted results. Forward-looking factors that may be discussed include, but are not limited to, future financial performance, new product development, governmental approvals, market potential and resulting sales as well as potential therapeutic applications, and additional acquisitions. These risks and uncertainties include market conditions and other factors beyond the Company's control and the economic, competitive, governmental, technological and other factors identified under the heading "Risk Factors" included in item IA of Integra's Annual Report on Form 10-K for the year ended December 31, 2007 and information contained in subsequent filings with the Securities and Exchange Commission could affect actual results.

IART-G

This news release was distributed by GlobeNewswire, www.globenewswire.com

SOURCE: Integra LifeSciences Holdings Corp.

Integra LifeSciences Holdings Corporation

John B. Henneman, III, Executive Vice President
Finance and Administration, and Chief Financial Officer
(609) 936-2481
jhenneman@Integra-LS.com

Karen Mroz-Bremner, Senior Manager, Corporate Development
and Investor Relations
(609) 936-6929
karen.mroz-bremner@integra-LS.com

(C) Copyright 2008 GlobeNewswire, Inc. All rights reserved.

News Provided by COMTEX